MUMBAI, India, Nov. 14 -- Intellectual Property India has published a patent application (202517094985 A) filed by Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (GMBH); Technische Universitat Munchen, In Vertretung Des Freistaates Bayern; Universitatsklinikum Hamburg-Eppendorf; and Albert-Ludwigs-Universitat Freiburg, Neuherberg, Germany, on Oct. 3, for 'hbv antigen formulation for treating hepatitis b.'
Inventor(s) include Protzer, Ulrike; Ambike, Shubhankar; Kosinska, Anna Dagmara; Thiele, Frank; Wiegand, Marian; Knolle, Percy; Addo, Marylyn Martina; and Nassal, Michael.
The application for the patent was published on Nov. 14, under issue no. 46/2025.
According to the abstract released by the Intellectual Property India: "The disclosure provides methods and compositions for treating HBV. Disclosed is an HBcAg particle, comprising HBV core proteins from at least two different HBV genotypes, and a vaccine vector comprising a nucleotide sequence having =90% sequence identity to SEQ ID NO: 5. Disclosed are respective pharmaceutical compositions and their uses in therapy, for medicament manufacture and a vaccination method. Said vaccination method comprises administering to a human (i) a first dose and (ii) a second dose of an HBcAg particle and of an HBsAg, and (iii) a dose of a vaccine vector that expresses a HBsAg from HBV genotype A, a HBcAg from HBV genotype D, a HBsAg having =90% sequence identity to SEQ ID NO: 7, a HBcAg having =90% sequence identity to SEQ ID NO: 8 or 17, and an RT domain having =90% sequence identity to SEQ ID NO: 9."
The patent application was internationally filed on Feb. 13, 2024, under International application No.PCT/EP2024/053631.
Disclaimer: Curated by HT Syndication.
